drugset / Trial / NCT00145236

Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate Hypertension

NCT00145236

Phase 3 Completed 300 enrolled Mylan Bertek Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study was to determine if nebivolol is superior to placebo for the treatment of elevated blood pressure in Black patients with mild to moderate hypertension.

Timeline

Start
2001-11
Primary completion
Completion
2003-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Nebivolol Other / unclassified

Indications